Brain tumours (primary or metastatic)

Indication for Lomustine

Population group: Suitable for both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

For this indication, competent medicine agencies globally authorize below treatments:

120-130 mg/m² once every 6-8 weeks

Route of admnistration


Defined daily dose

120 - 130 mg per m² of body surface area (BSA)

Dosage regimen

From 120 To 130 mg per m² of body surface area (BSA) once every 42 day(s) for 1 day(s)

Detailed description

Lomustine is given by mouth. The recommended dose in patients with normally functioning bone marrow receiving lomustine as their only chemotherapy is 120–130 mg/m² as a single dose every six to eight weeks (or as a divided dose over 3 days, e.g. 40 mg/m²/day).

Dosage is reduced:

  • if lomustine is given as part of a drug regimen which includes other marrow-depressant medicinal products.
  • in the presence of leucopenia below 3,000/mm³ or thrombocytopenia below 75,000/mm³.

Marrow depression after lomustine is sustained longer than after nitrogen mustards and recovery of white cell and platelet counts may not occur for six weeks or more. Blood elements depressed below the above levels should be allowed to recover to 4,000/mm³ (WBC) and 100,000/mm³ (platelets) before repeating lomustine dosage.

Active ingredient

Lomustine’s mode of action is believed to be partly as an alkylating agent and partly by inhibition of several steps in the synthesis of nucleic acid and inhibition of the repair of single strand breaks in DNA chains.

Read more about Lomustine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner